Cathal Friel, executive chairman and co-founder of Open Orphan (LSE:ORPH), presents a high-level summary of where the company is at currently, and answers a range of investor questions. The event, held on 2 June 2021, is brought to you by our friends at Investor Meet Company.
00:00 - presentation
31:48 - investor Q&A
Open Orphan IPO'd on the London and Dublin stock exchanges in June 2019.
Open Orphan plc is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.